
Patient-Oriented Evidence That Matters
ACG Guideline for Treatment of Helicobacter pylori Infection in Adults
Am Fam Physician. 2025;111(3):282-283
CLINICAL QUESTION
What does the American College of Gastroenterology (ACG) recommend for the treatment of Helicobacter pylori infection in adults?
BOTTOM LINE
The ACG recommendations have several nuances, but their only strong recommendation is that adults who are treatment-naïve should receive optimized bismuth quadruple therapy. (Level of Evidence = 5)
SYNOPSIS
The ACG convened a panel of clinical experts and methodologists (there is no mention of patients or primary care clinicians) to review the current evidence for the treatment of H pylori infection in adults. The panel weighed systematic reviews, meta-analyses, network meta-analyses, and individual randomized trials to answer 11 separate clinical questions. Similar to ACG’s other guidelines, it provides useful tables, algorithms, and charts. The authors made only one strong recommendation: in adults who were not previously treated, 14 days of optimized bismuth quadruple therapy, which consists of a proton pump inhibitor (PPI; standard dose twice daily), bismuth subcitrate (120–300 mg four times daily) or subsalicylate (300 mg four times daily), tetracycline (500 mg four times daily; do not substitute with doxycycline), and metronidazole (Flagyl; 500 mg three or four times daily) should be first-line treatment. The following are conditional recommendations for adults who are treatment-naïve:
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available